Microsatellite instability in sporadic gastric cancer

Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection

Ji Yeong An, Hyunki Kim, Jae Ho Cheong, WooJin Hyung, Hoguen Kim, Sung Hoon Noh

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

This study investigated whether MSI status can be used as a prognostic biomarker and whether it is helpful for predicting which patients will benefit from 5-FU based adjuvant chemotherapy. Between 2005 and 2008, an MSI status examination was performed in 1,990 gastric cancer patients who had undergone curative gastrectomy for gastric adenocarcinoma. MSI was analyzed by PCR amplification with fluorescent dye-labeled primers of mononucleotide markers (BAT25 and BAT26) and dinucleotide markers (D5S346, D2S123 and D17S250) specific to the microsatellite loci. Patients with MSI-H tumors accounted for 8.5% (n = 170) of the total study population. They tended to be older and female and to have distal tumor location, lower tumor stage, intestinal type of Lauren classification and differentiated histological type. The disease-free survival curves showed no significant differences between MSS/MSI-L and MSI-H patients at each stage of I, II, III and IV. In gastric cancer patients with stage II and III, 5-FU-based adjuvant chemotherapy showed better disease-free survival in the MSS/MSI-L group, but showed no benefits in the MSI-H group. By multivariate analysis, patients with MSS/MSI-L tumors benefited from 5-FU-based adjuvant chemotherapy in terms of tumor disease-free survival. MSI status in gastric cancer is not itself a prognostic indicator. However, it appears to be a possible guidance for the use of 5-FU-based chemotherapy in stage II and III gastric cancers after R0 resection.

Original languageEnglish
Pages (from-to)505-511
Number of pages7
JournalInternational Journal of Cancer
Volume131
Issue number2
DOIs
Publication statusPublished - 2012 Jul 15

Fingerprint

Microsatellite Instability
Fluorouracil
Stomach Neoplasms
Drug Therapy
Adjuvant Chemotherapy
Disease-Free Survival
Neoplasms
N-methylsuccinimide
Gastrectomy
Fluorescent Dyes
Microsatellite Repeats
Stomach
Adenocarcinoma
Multivariate Analysis
Biomarkers
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

An, Ji Yeong ; Kim, Hyunki ; Cheong, Jae Ho ; Hyung, WooJin ; Kim, Hoguen ; Noh, Sung Hoon. / Microsatellite instability in sporadic gastric cancer : Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. In: International Journal of Cancer. 2012 ; Vol. 131, No. 2. pp. 505-511.
@article{8c791a9db1e74542b446b4280945c283,
title = "Microsatellite instability in sporadic gastric cancer: Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection",
abstract = "This study investigated whether MSI status can be used as a prognostic biomarker and whether it is helpful for predicting which patients will benefit from 5-FU based adjuvant chemotherapy. Between 2005 and 2008, an MSI status examination was performed in 1,990 gastric cancer patients who had undergone curative gastrectomy for gastric adenocarcinoma. MSI was analyzed by PCR amplification with fluorescent dye-labeled primers of mononucleotide markers (BAT25 and BAT26) and dinucleotide markers (D5S346, D2S123 and D17S250) specific to the microsatellite loci. Patients with MSI-H tumors accounted for 8.5{\%} (n = 170) of the total study population. They tended to be older and female and to have distal tumor location, lower tumor stage, intestinal type of Lauren classification and differentiated histological type. The disease-free survival curves showed no significant differences between MSS/MSI-L and MSI-H patients at each stage of I, II, III and IV. In gastric cancer patients with stage II and III, 5-FU-based adjuvant chemotherapy showed better disease-free survival in the MSS/MSI-L group, but showed no benefits in the MSI-H group. By multivariate analysis, patients with MSS/MSI-L tumors benefited from 5-FU-based adjuvant chemotherapy in terms of tumor disease-free survival. MSI status in gastric cancer is not itself a prognostic indicator. However, it appears to be a possible guidance for the use of 5-FU-based chemotherapy in stage II and III gastric cancers after R0 resection.",
author = "An, {Ji Yeong} and Hyunki Kim and Cheong, {Jae Ho} and WooJin Hyung and Hoguen Kim and Noh, {Sung Hoon}",
year = "2012",
month = "7",
day = "15",
doi = "10.1002/ijc.26399",
language = "English",
volume = "131",
pages = "505--511",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

Microsatellite instability in sporadic gastric cancer : Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. / An, Ji Yeong; Kim, Hyunki; Cheong, Jae Ho; Hyung, WooJin; Kim, Hoguen; Noh, Sung Hoon.

In: International Journal of Cancer, Vol. 131, No. 2, 15.07.2012, p. 505-511.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Microsatellite instability in sporadic gastric cancer

T2 - Its prognostic role and guidance for 5-FU based chemotherapy after R0 resection

AU - An, Ji Yeong

AU - Kim, Hyunki

AU - Cheong, Jae Ho

AU - Hyung, WooJin

AU - Kim, Hoguen

AU - Noh, Sung Hoon

PY - 2012/7/15

Y1 - 2012/7/15

N2 - This study investigated whether MSI status can be used as a prognostic biomarker and whether it is helpful for predicting which patients will benefit from 5-FU based adjuvant chemotherapy. Between 2005 and 2008, an MSI status examination was performed in 1,990 gastric cancer patients who had undergone curative gastrectomy for gastric adenocarcinoma. MSI was analyzed by PCR amplification with fluorescent dye-labeled primers of mononucleotide markers (BAT25 and BAT26) and dinucleotide markers (D5S346, D2S123 and D17S250) specific to the microsatellite loci. Patients with MSI-H tumors accounted for 8.5% (n = 170) of the total study population. They tended to be older and female and to have distal tumor location, lower tumor stage, intestinal type of Lauren classification and differentiated histological type. The disease-free survival curves showed no significant differences between MSS/MSI-L and MSI-H patients at each stage of I, II, III and IV. In gastric cancer patients with stage II and III, 5-FU-based adjuvant chemotherapy showed better disease-free survival in the MSS/MSI-L group, but showed no benefits in the MSI-H group. By multivariate analysis, patients with MSS/MSI-L tumors benefited from 5-FU-based adjuvant chemotherapy in terms of tumor disease-free survival. MSI status in gastric cancer is not itself a prognostic indicator. However, it appears to be a possible guidance for the use of 5-FU-based chemotherapy in stage II and III gastric cancers after R0 resection.

AB - This study investigated whether MSI status can be used as a prognostic biomarker and whether it is helpful for predicting which patients will benefit from 5-FU based adjuvant chemotherapy. Between 2005 and 2008, an MSI status examination was performed in 1,990 gastric cancer patients who had undergone curative gastrectomy for gastric adenocarcinoma. MSI was analyzed by PCR amplification with fluorescent dye-labeled primers of mononucleotide markers (BAT25 and BAT26) and dinucleotide markers (D5S346, D2S123 and D17S250) specific to the microsatellite loci. Patients with MSI-H tumors accounted for 8.5% (n = 170) of the total study population. They tended to be older and female and to have distal tumor location, lower tumor stage, intestinal type of Lauren classification and differentiated histological type. The disease-free survival curves showed no significant differences between MSS/MSI-L and MSI-H patients at each stage of I, II, III and IV. In gastric cancer patients with stage II and III, 5-FU-based adjuvant chemotherapy showed better disease-free survival in the MSS/MSI-L group, but showed no benefits in the MSI-H group. By multivariate analysis, patients with MSS/MSI-L tumors benefited from 5-FU-based adjuvant chemotherapy in terms of tumor disease-free survival. MSI status in gastric cancer is not itself a prognostic indicator. However, it appears to be a possible guidance for the use of 5-FU-based chemotherapy in stage II and III gastric cancers after R0 resection.

UR - http://www.scopus.com/inward/record.url?scp=84861613037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861613037&partnerID=8YFLogxK

U2 - 10.1002/ijc.26399

DO - 10.1002/ijc.26399

M3 - Article

VL - 131

SP - 505

EP - 511

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -